Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | GFER | P55789 | 1/20 | 0.61 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.61 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.45 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2762402 | 0.83 | PARP10 (0.66) | ALOX15GFERADAM17ATMALDH1A1 | |
| SCHEMBL7042503 | 0.83 | ALOX15 (0.66) | ALOX15GFERADAM17ATMALDH1A1 | |
| SCHEMBL2791684 | 0.83 | ALOX15 (0.66) | ALOX15GFERADAM17ATMALDH1A1 | |
| SCHEMBL28208867 | 0.81 | ALOX15 (0.63) | ALOX15GFERADAM17ATMALDH1A1 | |
| SCHEMBL1018588 | 0.81 | KMT2A (0.64) | ALOX15GFERADAM17ATMALDH1A1 | |
| SCHEMBL24400226 | 0.81 | ALOX15 (0.63) | ALOX15GFERADAM17ATMALDH1A1 | |
| SCHEMBL1906677 | 0.79 | ALOX15 (0.61) | ALOX15GFERADAM17ATMALDH1A1 | |
| Hydrochloric Acid SCHEMBL9015381 | 0.79 | KMT2A (0.62) | ALOX15GFERADAM17ATMALDH1A1 | |
| SCHEMBL2422073 | 0.79 | ALOX15 (0.61) | ALOX15GFERADAM17ATMALDH1A1 | |
| SCHEMBL2094738 | 0.79 | PARP10 (0.71) | ALDH1A1HTTMEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103906746-B | (4-phenylimidazol-2-yl) ethylamine derivatives as sodium channel modulators | PFIZER LTD. (GB) | 2015-12-09 | — | — | CN | disclosed |
| US-9079878-B2 | (4-phenylimidazol-2-yl) ethylamine derivatives useful as sodium channel modulators | PFIZER LIMITED (GB) | 2015-07-14 | — | — | US | disclosed |
| US-20140296313-A1 | (4-Phenylimidazol-2-yl) Ethylamine Derivatives Useful As Sodium Channel Modulators | PFIZER LIMITED (GB) | 2014-10-02 | — | — | US | disclosed |
| EP-2771335-A2 | (4-PHENYLIMIDAZOL-2-YL) ETHYLAMINE DERIVATIVES USEFUL AS SODIUM CHANNEL MODULATORS | Pfizer Limited (GB) | 2014-09-03 | — | — | EP | disclosed |
| CN-103906746-A | (4-phenylimidazol-2-yl) ethylamine derivatives as sodium channel modulators | PFIZER | 2014-07-02 | — | — | CN | disclosed |
| WO-2013061205-A2 | CHEMICAL COMPOUNDS | PFIZER LIMITED (GB) | 2013-05-02 | — | — | WO | disclosed |
| US-8202891-B2 | Quaternary ammonium compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-20080269190-A1 | Chronic obstructive pulmonary disease; asthma | THERAVANCE, INC. | 2008-10-30 | — | — | US | disclosed |
| EP-0702013-B1 | Imidazopyridines | MERCK PATENT GMBH (DE) | 2001-06-13 | — | — | EP | disclosed |
| US-5684015-A | ANGIOTENSIN ANTAGONIST AS HYPOTENSIVE AGENTS AND CARDIOVASCULAR DISORDERS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1997-11-04 | — | — | US | disclosed |
| EP-0702013-A2 | Imidazopyridines | MERCK PATENT GmbH (DE) | 1996-03-20 | — | — | EP | disclosed |
| US-5438063-A | Hypotensive agents, cardiac insufficiency, increased intraocular pressure, and CNS disorders | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1995-08-01 | — | — | US | disclosed |
| EP-0657454-A1 | Imidazopyridazines being angiotensin II antagonists | MERCK PATENT GmbH (DE) | 1995-06-14 | — | — | EP | disclosed |
| US-5389642-A | Exhibit antagonistic properties toward angiotensin(II); useful for treatment of hypertensioni, aldosteronism, cardiac insufficiency, increased intraocular pressure and disorders of the central nervous system | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1995-02-14 | — | — | US | disclosed |
| EP-0628556-A1 | Imidazopyridines | MERCK PATENT GmbH (DE) | 1994-12-14 | — | — | EP | disclosed |
| EP-0602521-A1 | Imidazopyridines | MERCK PATENT GmbH (DE) | 1994-06-22 | — | — | EP | disclosed |
| US-5242928-A | Angiotensin II antagonists | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1993-09-07 | — | — | US | disclosed |
| EP-0547514-A2 | Imidazopyridine derivatives with angiotensin-II antagonist properties | MERCK PATENT GmbH (DE) | 1993-06-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269190-A1 | Chronic obstructive pulmonary disease; asthma | CHRM2, CHRM5, CHRM3 | ALOX15 1648/4885GFER 2149/4885ADAM17 3632/4885 |
| US-20140296313-A1 | (4-Phenylimidazol-2-yl) Ethylamine Derivatives Useful As Sodium Channel Modulators | SCN8A, SCN1A, SCN5A | ALOX15 4747/4885GFER 4215/4885ADAM17 4399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.